Unresectable metastatic non-small-cell lung cancer (NSCLC) patients without genetic alterations are now treated, in first-line treatment, with ICIs in monotherapy or in combination with chemotherapy depending on the level of tumor PD-L1 expression [2,3]. This evidence concerns the gene CD274 and neoplasm.